[Hepatic transplantation]

Area of Science:

• Hepatology
• Transplantation Surgery
• Immunology

Background:

• Liver transplantation (LT) has evolved significantly since 1963, becoming a standard treatment for end-stage liver diseases.
• Indications have expanded, with early-stage hepatocellular carcinoma, cirrhosis (Hepatitis C and alcoholic), being primary adult reasons.
• European data shows 5000 LTs annually, with survival rates of 86% at 1 year, 75% at 5 years, and 68% at 10 years (2000-2006).

Purpose of the Study:

• To review the advancements and current status of liver transplantation.
• To identify the primary challenges and future research directions in the field.
• To highlight the progress in surgical techniques, immunosuppression, and organ allocation.

Main Methods:

• Review of historical data and current practices in liver transplantation.
• Analysis of survival rates and indications for LT in Europe.
• Discussion of advancements in immunosuppressive drugs and organ procurement strategies.

Main Results:

• Significant improvements in surgical techniques, immunosuppression (tacrolimus, mycophenolic acid, etc.), and organ allocation policies have enhanced LT outcomes.
• Rejection incidence is now less than 20% due to advanced immunosuppressive drugs.
• Surgical innovations like split liver, domino LT, and living donor transplantation have expanded organ availability.

Conclusions:

• Liver transplantation is a successful treatment for end-stage liver disease, but organ shortage and long-term immunosuppression complications remain significant hurdles.
• Future efforts should focus on optimizing organ recruitment (e.g., non-heart beating donation, intrafamilial donation) and developing novel immunosuppressive strategies to induce tolerance.
• Research into molecular signatures of tolerant patients and methods like lymphocyte depletion or costimulation blockade are promising for reducing immunosuppression-related complications.